XTX Topco Ltd increased its position in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) by 1.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,232 shares of the company’s stock after purchasing an additional 665 shares during the period. Guardant Health accounts for about 0.3% of XTX Topco Ltd’s investment portfolio, making the stock its 26th largest holding. XTX Topco Ltd owned 0.06% of Guardant Health worth $1,342,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in GH. US Bancorp DE increased its holdings in shares of Guardant Health by 5.2% in the first quarter. US Bancorp DE now owns 12,808 shares of the company’s stock valued at $849,000 after buying an additional 632 shares in the last quarter. MetLife Investment Management LLC purchased a new stake in shares of Guardant Health in the first quarter valued at $385,000. Vontobel Holding Ltd. lifted its holdings in shares of Guardant Health by 20.3% in the first quarter. Vontobel Holding Ltd. now owns 16,548 shares of the company’s stock valued at $1,109,000 after purchasing an additional 2,797 shares in the last quarter. Bridgewater Associates LP lifted its holdings in shares of Guardant Health by 36.0% in the first quarter. Bridgewater Associates LP now owns 143,041 shares of the company’s stock valued at $9,475,000 after purchasing an additional 37,888 shares in the last quarter. Finally, First Trust Advisors LP increased its stake in shares of Guardant Health by 186.3% in the first quarter. First Trust Advisors LP now owns 24,392 shares of the company’s stock worth $1,616,000 after acquiring an additional 15,873 shares during the last quarter. Institutional investors own 92.65% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently weighed in on GH shares. Citigroup upped their price target on shares of Guardant Health from $40.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, August 4th. Morgan Stanley lowered their target price on shares of Guardant Health from $60.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 7th. William Blair reissued an “outperform” rating on shares of Guardant Health in a research report on Friday. Finally, Piper Sandler increased their target price on shares of Guardant Health from $30.00 to $40.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 8th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $56.87.
Guardant Health Trading Down 4.4 %
Shares of NASDAQ:GH opened at $33.72 on Friday. The company has a market cap of $3.97 billion, a P/E ratio of -6.87 and a beta of 0.87. The stock’s 50-day moving average is $37.05 and its 200-day moving average is $31.29. Guardant Health, Inc. has a 52-week low of $20.67 and a 52-week high of $62.75. The company has a debt-to-equity ratio of 3.89, a quick ratio of 6.65 and a current ratio of 6.96.
Guardant Health (NASDAQ:GH – Get Free Report) last released its earnings results on Thursday, August 3rd. The company reported ($0.67) earnings per share for the quarter, beating the consensus estimate of ($1.25) by $0.58. Guardant Health had a negative net margin of 99.62% and a negative return on equity of 427.89%. The business had revenue of $137.15 million during the quarter, compared to analysts’ expectations of $129.44 million. During the same quarter last year, the company earned ($2.25) earnings per share. The firm’s revenue was up 25.7% on a year-over-year basis. Equities research analysts predict that Guardant Health, Inc. will post -3.77 earnings per share for the current year.
Insider Activity at Guardant Health
In related news, Director Meghan V. Joyce sold 2,766 shares of the stock in a transaction dated Thursday, June 15th. The shares were sold at an average price of $37.55, for a total value of $103,863.30. Following the completion of the sale, the director now owns 4,224 shares in the company, valued at $158,611.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 6.20% of the stock is owned by corporate insiders.
Guardant Health Profile
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360; Guardant360 LDT; Guardant360 CDx; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
- Five stocks we like better than Guardant Health
- How to Invest in Small Cap Stocks
- The Best 5 Small Cap AI Companies to Buy Now
- How to Invest in Energy
- Miso Robotics Stock: Is an IPO Coming Soon?
- What Investors Need to Know to Beat the Market
- 3 Stocks to Play the Easing Food Supply Chain
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.